Erythropoietin Triggers a Signaling Pathway in Endothelial Cells and Increases the Thrombogenicity of their Extracellular Matrices In Vitro

 

 Buy Article Permissions and Reprints

Summary

We demonstrate that exposure of cultured human endothelial cells to rHuEPO resulted in a dose-dependent increase in the tyrosine kinase activity, with phosphorylation of JAK-2 followed by rapid phosphorylation of STAT-5. Simultaneously, rHuEPO induced long-lasting phosphorylation of MAPK p42/44. Activation of this signaling pathways was directly associated with an increase in the thrombogenic properties of the extracellular matrix generated by these cells, when they were exposed to flowing blood. The enhancement in the reactivity of the resulting extracellular matrix towards platelets was associated with a higher expression of tissue factor. All these effects were blocked by an antibody to the EPO receptor and by specific inhibitors of tyrosine phosphorylation. The observed action of rHuEPO on endothelial cells seemed to be specifically triggered by the subsequent events that follow receptor binding, and occurred even at pharmacological concentrations of the cytokine. Our results indicate that rHuEPO has a direct action on the endothelium, increasing the reactivity of the underlying extracellular matrix towards platelets, effect that may be attributed to an increase in the expression of TF.

• References

• 1 Kranz SB. Erythropoietin. Blood 1991; 77: 419-34.
  PubMedGoogle Scholar
• 2 Papayannopoulou T, Brice M, Farrer D, Kaushansky K. Insights into the cellular mechanism of erythropoietin-thrombopoietin synergy. Exp Hematol 1996; 24: 660-9.
  PubMedGoogle Scholar
• 3 Hawrylowicz CM. Viewpoint: A pontencial role for platelets derived cytokines in the inflammatory response. Platelets 1993; 04: 1-10.
  PubMedGoogle Scholar
• 4 Eschbach JW, Egriev JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-8.
  CrossrefPubMedGoogle Scholar
• 5 Remuzzi G. Bleeding in renal failure. Lancet 1988; 01: 1205-8.
  PubMedGoogle Scholar
• 6 Moia M, Mannucci PM, Vizzotto L, Casati S, Cattaneo M, Ponticelli C. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoeitin. Lancet 1987; ii: 1227-9.
  PubMedGoogle Scholar
• 7 Fernandez F, Goudable C, Sie P, Ton-That H, Durand D, Suc JM, Boneu B. Low hematocrit and prolonged bleeding time in uraemic patients: Effect of red cell transfusions. Br J Haematol 1985; 59: 139-48.
  CrossrefPubMedGoogle Scholar
• 8 Zwaginga JJ, Ijsseldijk MJ, de Groot PG, Kooistra M, Vos J, van Es A, Koomans HA, Struyvenberg A, Sixma JJ. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma. Thromb Haemost 1991; 66: 638-47.
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Cases A, Escolar G, Reverter JC, Ordinas A, Lopez-Pedret J, Revert L, Castillo R. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 1992; 42: 668-72.
  CrossrefPubMedGoogle Scholar
• 10 Diaz-Ricart M, Estebanell E, Cases A, Lopez-Pedret J, Castillo R, Ordinas A, Escolar G. Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients. Thromb Haemost 1999; 82: 1312-7.
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Jilma PStohlawetz, Dzirlo L, Hergovich N, Lackner E, Mensik Ch, Eichelr HG, Kabrna E, Geissler K, Jilma B. Effects of erythropoietin on platelet reactivity and thrompoiesis in humans. Blood 2000; 95: 2983-9.
  PubMedGoogle Scholar
• 12 Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990; 87: 587-91.
  PubMedGoogle Scholar
• 13 Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995; 47: 740-5.
  CrossrefPubMedGoogle Scholar
• 14 Haller H, Christel C, Dannenberg L, Thiele P, Lindschau C, Luft FC. Signal transduction of erythropoietin in endothelial cells. Kidney Int 1996; 50: 481-8.
  CrossrefPubMedGoogle Scholar
• 15 Gordge MP, Petel A, Faint RW, Rylance PB, Neild GH. Blood hyperviscosity and its relationship to progressive renal failure in patients with diabetic nephropaty. Diabet Med 1990; 07: 880-6.
  CrossrefPubMedGoogle Scholar
• 16 Raine AEG. Hypertension, blood viscosity, and cardiovascular morbidity in the renal failure: Implications of erythropoietin therapy. Lancet 1988; 01: 97.
  PubMedGoogle Scholar
• 17 Baskin S, Lasker D. Erythropoietin-associated hypertenssion. N Engl J Med 1990; 323: 999-1000.
  CrossrefPubMedGoogle Scholar
• 18 Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney 1991; 39: 259-65.
  CrossrefPubMedGoogle Scholar
• 19 Singbartl G. Adverse events of erythropoietin in long term and in acute/ short-term treatment. Clin Invest 1994; 72: S36-S43.
  PubMedGoogle Scholar
• 20 Serradell M, Díaz-Ricart M, Cases A, Zurbano MJ, Aznar-Salatti J, López-Pedret J, Ordinas A, Escolar G. Uremic medium disturbs the hemostatic balance of cultured human endothelial cells. Thromb Haemost 2001; 86: 1099-105.
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 Malyszko JS, Malyszko J, Pawlak K, Pawlak D, Buczko W, Mysliwiec M. Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin. Nephron 2000; 84: 305-11.
  CrossrefPubMedGoogle Scholar
• 22 Jaffe EA, Nachman RL, Becker CG. Culture of human endothelial cells derived from umbilical veins. J Clin Invest 1973; 52: 2745-56.
  CrossrefPubMedGoogle Scholar
• 23 Aznar-Salatti J, Diaz-Ricart M, Anton P, Bastida E, Escolar G, Ordinas A. Variations in the thrombogenic properties of the extracellular matrix produced by endothelial cells in consecutive passages. Sangre. (Barc) 1990; 35: 173-7.
  PubMedGoogle Scholar
• 24 Towbin H, Stachelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose: Procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4.
  CrossrefPubMedGoogle Scholar
• 25 Cichowski K, Brugge JS, Brass LF. Thrombin receptor activation and integrin engagement stimulate tyrosine phosphorylation of the protooncogene product, p95(vav), in platelets. J Biol Chem 1996; 271: 7544-50.
  CrossrefPubMedGoogle Scholar
• 26 Sakariassen KS, Aarts PA, de Groot PG, Houdijk WP, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med 1983; 102: 522-35.
  PubMedGoogle Scholar
• 27 Diaz-Ricart M, Carretero M, Castillo R, Ordinas A, Escolar G. Digital image analysis of platelet-extracellular matrix interactions: studies in von willebrand disease patients and aspirin-treated donors. Haemostasis 1994; 24: 219-29.
  PubMedGoogle Scholar
• 28 De Mey J, Moeremans M, Geuens G, Nuydens R, De Brabander M. High resolution light and electron microscopic localization of tubulin with the IGS (inmunogold staining) method. Cell Biol Int Rep 1981; 05: 889-99.
  CrossrefPubMedGoogle Scholar
• 29 Scopsi L, Larsson LI, Bastholm L, Nielsen MH. Silver-Enhanced colloidal gold probes as markers for scanning electron microscopy. Histochem J 1986; 86: 35-41.
  CrossrefPubMedGoogle Scholar
• 30 Ihle J. Stats. Signal transducers and activators of transcription. Cell 1996; 84: 331-4.
  CrossrefPubMedGoogle Scholar
• 31 Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle J. JAK-2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993; 74: 227-36.
  CrossrefPubMedGoogle Scholar
• 32 Sabin F. Studies of the origin of blood vessels and of red corpuscles as seen in the living blastoderms of chicks during the second day of incubation. Contrib Embriol Carnege Inst Washington 1920; 09: 214.
  PubMedGoogle Scholar
• 33 Anagnostou A, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994; 91: 3974-8.
  CrossrefPubMedGoogle Scholar
• 34 Ihle J. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001; 13: 211-7.
  CrossrefPubMedGoogle Scholar
• 35 Valdembri D, Serini G, Vacca A, Ribatti D, Bussolino F. In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEBJ 2002; 16: 225-7.
  CrossrefPubMedGoogle Scholar
• 36 Klingmüller U. The role of tyrosine phosphorylation in proliferation and maduration of erythroid progenitor cells: Signal emanating from the erythropoietin receptor. EJB 1997; 249: 637-47.
  CrossrefPubMedGoogle Scholar
• 37 Metcalf D. The molecular control of cell division, differentiation, commitment and maturation in haematopoietic cells. Nature 1989; 339: 27-30.
  CrossrefPubMedGoogle Scholar
• 38 Ratajckak J, Majka M, Kijowski J, Baj M, Pan ZK, Marquez LA, Janowska-Wieczorek A, Ratajczak MZ. Biological significance of MAPK, AKT and JAK-STAT protein activation by various erythropoietic factors in normal human early erythroid cells. Br J Haematol 2001; 115: 195-204.
  CrossrefPubMedGoogle Scholar
• 39 Ribatti D, Presta M, Vacca A, Ria R, Giulani R, Dell’Era P, Nico B, Roncalli L, Dammaco F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularitzation in vivo. Blood 1999; 93: 2627-36.
  PubMedGoogle Scholar
• 40 Beckman DL, Lin LL, Quinones ME, Longmore GD. Activation of the erythropoietin receptor is not required for internalization of bound erythropoietin. Blood 1999; 94: 2667-75.
  PubMedGoogle Scholar
• 41 Nagata Y, Takahashi N, Davis RJ, Todokoro K. Activation of p38 MAP Kinase and JNK but not ERK is required for erythropoietin-induced erythropoietin differentation. Blood 1998; 92: 1859-69.
  PubMedGoogle Scholar
• 42 Rao LVM, Rapaport SI, Bajaj SP. Activation of human factor VII in the initiation of tissue factor-dependent coagulation. Blood 1986; 65: 685-91.
  PubMedGoogle Scholar
• 43 Weiss HJ, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988; 71: 629-35.
  PubMedGoogle Scholar
• 44 Nemerson Y. Tissue factor and haemostasis. Blood 1988; 71: 1-8.
  PubMedGoogle Scholar
• 45 de Groot PG, Reinders JH, Sixma JJ. Perturbation of human endothelial cells by thrombin or PMA changes the reactivity of their extracellular matrix towards platelets. J Cell Biol 1987; 104: 697-704.
  CrossrefPubMedGoogle Scholar
• 46 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-97.
  PubMedGoogle Scholar
• 47 Mulder AB, Karin SM, Heggepaping KSM, Magielse CPE, Blom NR, Smit JW, Vandermeer J, Halie MR, Bom VJJ. Tumor necrosis factor α-induced endothelial tissue factor is located on the cell surface rather than in the subendothelial matrix. Blood 1994; 84: 1559-66.
  PubMedGoogle Scholar
• 48 Galvez A, Gomez-Ortiz G, Diaz-Ricart M, Escolar G, Gonzalez-Sarmiento R, Zurbano MJ, Ordinas A, Castillo R. Desmopressin (DDAVP) enhances platelet adhesion to the extracellular matrix of cultured human endothelial cells through increased expression of tissue factor. Thromb Haemost 1997; 77: 975-80.
  Article in Thieme ConnectPubMedGoogle Scholar
• 49 Orvim U, Roald HE, Stephens RW, Roos N, Sakariassen KS. Tissue factorinduced coagulation triggers platelet thrombus formation as efficiently as fibrillar collagen at arterial blood flow conditions. Arterioscler Thromb 1994; 14: 1976-83.
  CrossrefPubMedGoogle Scholar